AIHTA - Publications - Search - Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update March 2023

Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update March 2023. Fact Sheet Nr. 111.

[thumbnail of Fact Sheet Nr.111.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
747kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WH Hemic and lymphatic systems
Language:English
Series Name:Fact Sheet Nr. 111
Deposited on:17 Oct 2022 12:21
Last Modified:02 Oct 2023 10:54

Repository Staff Only: item control page